One year follow-up cardiovascular outcomes of Coraxel brand paclitaxel eluting stents: a single center experience
Coraxel (Alvimedica) stents are among those that contain paclitaxel and differ from other paclitaxel eluting stents (PES) in the amount of drug they contain. In this context, it is not known whether the clinical effects of Coraxel stents are different or not. In this study, the clinical effects of C...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Society of Turaz Bilim
2017-06-01
|
| Series: | Medicine Science |
| Subjects: | |
| Online Access: | http://www.ejmanager.com/fulltextpdf.php?mno=248165 |
| _version_ | 1827361254263488512 |
|---|---|
| author | Fatih Levent Sadik Volkan Emren Nihan Kahya Eren Cem Nazli Hamza Duygu |
| author_facet | Fatih Levent Sadik Volkan Emren Nihan Kahya Eren Cem Nazli Hamza Duygu |
| author_sort | Fatih Levent |
| collection | DOAJ |
| description | Coraxel (Alvimedica) stents are among those that contain paclitaxel and differ from other paclitaxel eluting stents (PES) in the amount of drug they contain. In this context, it is not known whether the clinical effects of Coraxel stents are different or not. In this study, the clinical effects of Coraxel stents were studied. This study was a single-centered, prospective, non-randomized real life study. Patients to whom stents of Coraxel brand were implanted were followed up in 1-, 3-, 6- and 12-month periods between May 2011 and August 2013 for target lesion revascularization (TLR), stent thrombosis and major cardiovascular events. This study enrolled a total of 78 cases. 82.1% of the cases were male. Average age was 61±11 years. Average stent length was 26.91±11.24 mm, and average stent size was 2.73±0.28 mm. 28% of the patients had TLR, 5 (6%) cases had stent thrombosis, 3 (4%) cases death from all causes, 1 (1%) case cardiac death and 55% of the cases showed major cardiovascular events. TLR, major cardiovascular event and stent thrombosis were observed more frequently in the patients using Coraxel PSS compared to those using TAXUS PSS. [Med-Science 2017; 6(2.000): 305-9] |
| first_indexed | 2024-03-08T07:01:25Z |
| format | Article |
| id | doaj.art-12608cedeb7547f687cb39497326063c |
| institution | Directory Open Access Journal |
| issn | 2147-0634 |
| language | English |
| last_indexed | 2024-03-08T07:01:25Z |
| publishDate | 2017-06-01 |
| publisher | Society of Turaz Bilim |
| record_format | Article |
| series | Medicine Science |
| spelling | doaj.art-12608cedeb7547f687cb39497326063c2024-02-03T05:37:16ZengSociety of Turaz BilimMedicine Science2147-06342017-06-0162305910.5455/medscience.2016.05.8562248165One year follow-up cardiovascular outcomes of Coraxel brand paclitaxel eluting stents: a single center experienceFatih Levent0Sadik Volkan Emren1Nihan Kahya Eren2Cem Nazli3Hamza Duygu4Izmir Su Hospital Department of Cardiology Afyonkarahisar State Hospital Department of Cardiology Katip Celebi University Ataturk Training and Research Hospital Department of Cardiology Katip Celebi University Ataturk Training and Research Hospital Department of Cardiology Near East University School of Medicine Department of CardiologyCoraxel (Alvimedica) stents are among those that contain paclitaxel and differ from other paclitaxel eluting stents (PES) in the amount of drug they contain. In this context, it is not known whether the clinical effects of Coraxel stents are different or not. In this study, the clinical effects of Coraxel stents were studied. This study was a single-centered, prospective, non-randomized real life study. Patients to whom stents of Coraxel brand were implanted were followed up in 1-, 3-, 6- and 12-month periods between May 2011 and August 2013 for target lesion revascularization (TLR), stent thrombosis and major cardiovascular events. This study enrolled a total of 78 cases. 82.1% of the cases were male. Average age was 61±11 years. Average stent length was 26.91±11.24 mm, and average stent size was 2.73±0.28 mm. 28% of the patients had TLR, 5 (6%) cases had stent thrombosis, 3 (4%) cases death from all causes, 1 (1%) case cardiac death and 55% of the cases showed major cardiovascular events. TLR, major cardiovascular event and stent thrombosis were observed more frequently in the patients using Coraxel PSS compared to those using TAXUS PSS. [Med-Science 2017; 6(2.000): 305-9]http://www.ejmanager.com/fulltextpdf.php?mno=248165Drug eluting stentstarget lesion revascularizationstent thrombosismajor cardiovascular events |
| spellingShingle | Fatih Levent Sadik Volkan Emren Nihan Kahya Eren Cem Nazli Hamza Duygu One year follow-up cardiovascular outcomes of Coraxel brand paclitaxel eluting stents: a single center experience Medicine Science Drug eluting stents target lesion revascularization stent thrombosis major cardiovascular events |
| title | One year follow-up cardiovascular outcomes of Coraxel brand paclitaxel eluting stents: a single center experience |
| title_full | One year follow-up cardiovascular outcomes of Coraxel brand paclitaxel eluting stents: a single center experience |
| title_fullStr | One year follow-up cardiovascular outcomes of Coraxel brand paclitaxel eluting stents: a single center experience |
| title_full_unstemmed | One year follow-up cardiovascular outcomes of Coraxel brand paclitaxel eluting stents: a single center experience |
| title_short | One year follow-up cardiovascular outcomes of Coraxel brand paclitaxel eluting stents: a single center experience |
| title_sort | one year follow up cardiovascular outcomes of coraxel brand paclitaxel eluting stents a single center experience |
| topic | Drug eluting stents target lesion revascularization stent thrombosis major cardiovascular events |
| url | http://www.ejmanager.com/fulltextpdf.php?mno=248165 |
| work_keys_str_mv | AT fatihlevent oneyearfollowupcardiovascularoutcomesofcoraxelbrandpaclitaxelelutingstentsasinglecenterexperience AT sadikvolkanemren oneyearfollowupcardiovascularoutcomesofcoraxelbrandpaclitaxelelutingstentsasinglecenterexperience AT nihankahyaeren oneyearfollowupcardiovascularoutcomesofcoraxelbrandpaclitaxelelutingstentsasinglecenterexperience AT cemnazli oneyearfollowupcardiovascularoutcomesofcoraxelbrandpaclitaxelelutingstentsasinglecenterexperience AT hamzaduygu oneyearfollowupcardiovascularoutcomesofcoraxelbrandpaclitaxelelutingstentsasinglecenterexperience |